English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To the Editor: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapy for patients with acute myelogenous leukemia (AML) due to the intensive conditioning chemoradiotherapy and the effect of graft-versus-leukemia (GVL). An isolated extramedullary (EM) relapse of acute leukemia (AL) is a rare occurrence observed more commonly after allo-HSCT rather than following conventional chemotherapy alone.[1] The prognosis of patients with EM relapse is less favorable than bone marrow (BM) relapse, and there are no standard therapies.

chinese medical journal/chinese medical journal

Paraplegia as Manifestation of an Isolated Central Nervous System Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in a Woman with Acute Myelogenous Leukemia